Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion type Assertion NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_head.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion description "[HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion evidence source_evidence_literature NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion SIO_000772 24518603 NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion wasDerivedFrom befree-20150227 NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.
- NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_assertion wasGeneratedBy ECO_0000203 NP401799.RAjQP65DK457felKHIX-18qZy_OLYZNrMJ510RbgOrR4M130_provenance.